Welcome to our dedicated page for Moderna news (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.
Moderna, Inc. (NASDAQ: MRNA) is a biotechnology company focused on mRNA medicines, with multiple approved vaccines and a broad clinical pipeline. The MRNA news page on Stock Titan aggregates company announcements, investor updates and regulatory developments so readers can follow how Moderna’s strategy and pipeline progress translate into real-world events.
Investors and observers can use this feed to track commercial updates on products such as Spikevax, mRESVIA and mNEXSPIKE, along with developments in late-stage respiratory programs like the seasonal influenza vaccine mRNA-1010, the flu/COVID combination vaccine mRNA-1083 and the Norovirus vaccine candidate mRNA-1403. News items often cover regulatory submissions and opinions from agencies including the U.S. Food and Drug Administration, the European Medicines Agency, Health Canada and others.
The page also surfaces pipeline and clinical trial news in oncology and rare diseases, including updates on mRNA-4157 (intismeran autogene), mRNA-4359, mRNA-3927 for propionic acidemia and mRNA-3705 for methylmalonic acidemia. Announcements related to partnerships, such as CEPI’s funding commitment for the H5 pandemic influenza vaccine candidate mRNA-1018, appear here as well.
In addition, the MRNA news feed includes financial results, guidance and capital structure updates, such as quarterly earnings releases, multi-year financial frameworks and information on facilities like the $1.5 billion credit agreement. Corporate items, including participation in healthcare conferences, Analyst Day presentations and shareholder meeting outcomes, are also reflected.
By reviewing this consolidated news stream, readers can see how Moderna’s respiratory vaccine franchise, oncology and rare disease programs, manufacturing expansion and financing decisions evolve over time, all based on the company’s own disclosures and related announcements.
Moderna (NASDAQ: MRNA) has signed a new supply agreement with the Swiss Federal Government for seven million doses of its COVID-19 booster vaccine to be delivered in 2023. This adds to a previous agreement for seven million doses in the second half of 2022. CEO Stéphane Bancel emphasized the importance of booster doses in managing infection rates. The vaccine, SPIKEVAX, is authorized for individuals aged 12 and older, contributing to Moderna's robust portfolio in mRNA therapeutics. The company continues to expand its manufacturing capabilities and strategic collaborations.
Moderna, Inc. (MRNA) has submitted a request to the U.S. FDA to amend the emergency use authorization for its COVID-19 vaccine (mRNA-1273) to permit a fourth dose for adults aged 18 and older. The request aims to provide flexibility for healthcare providers and the CDC in administering additional booster doses, particularly for high-risk individuals. This submission relies on recent data from the U.S. and Israel, especially following the emergence of the Omicron variant. Moderna continues to collect real-world data to validate the vaccine's safety and effectiveness.
Moderna has received approval from Health Canada for its mRNA COVID-19 vaccine, SPIKEVAX, for children aged 6 to 11 years. This follows similar authorizations in both Australia and the European Union. The approval is based on data from the Phase 2/3 KidCOVE study, which demonstrated safety and efficacy in over 4,000 children. The vaccine displayed non-inferior antibody responses compared to older age groups. This marks a significant step in expanding vaccination efforts among younger populations.
Moderna, Inc. (NASDAQ:MRNA) has announced a deal with Japan's Ministry of Health to supply an additional 70 million doses of its COVID-19 booster vaccine in the second half of 2022. This agreement could increase the total contracted doses for Japan from 93 million to 163 million. The vaccine has received special approval for use in preventing COVID-19, with booster doses recommended for adults six months after the second dose. The agreement is contingent upon securing the necessary budget from the Ministry.
Moderna (Nasdaq:MRNA) announced the first participant has been dosed in its Phase 1 trial (HVTN 302) for an experimental HIV trimer mRNA vaccine (mRNA-1574). This multicenter, randomized trial aims to assess safety and immunogenicity in approximately 100 HIV-negative adults aged 18 to 55. Moderna's strategy involves using mRNA to induce protective HIV neutralizing antibodies. The trial is sponsored by the Division of AIDS at NIAID and aims to advance Moderna's capabilities in mRNA technology for HIV prevention.
Moderna has initiated a Phase 2 study of its Omicron-specific bivalent booster candidate (mRNA-1273.214), which combines mRNA-1273.529 and the original COVID-19 vaccine, mRNA-1273. The trial aims to enroll approximately 375 participants across 20 sites in the U.S. and will assess the immunogenicity, safety, and reactogenicity of the booster in adults. The study marks an extension of prior research and aligns with Moderna's commitment to adapt vaccines for emerging variants. Results will be shared with public health authorities ahead of the upcoming booster season.
Moderna, Inc. (NASDAQ:MRNA) will host its virtual Vaccines Day for analysts and investors on March 24, 2022, at 8:00 a.m. ET. The event will feature management presentations and insights from key opinion leaders regarding Moderna's mRNA vaccines and important developmental considerations. A live webcast will be accessible in the Investors section of the Moderna website, with a replay available for one year thereafter. Moderna has evolved to become a leading mRNA therapeutics and vaccines company, contributing significantly to pandemic efforts with its COVID-19 vaccine.
Moderna has unveiled a new global public health strategy through four key initiatives aimed at advancing mRNA vaccines for infectious diseases. The company plans to develop vaccines targeting 15 priority pathogens by 2025. Additionally, mRNA Access will allow researchers worldwide to utilize Moderna's mRNA technology. The company has also expanded its patent pledge, ensuring no enforcement in 92 low- and middle-income countries. Notably, Moderna will establish its first mRNA manufacturing facility in Kenya, investing up to $500 million to produce up to 500 million doses annually.
Moderna is investing up to $500 million to establish its first mRNA manufacturing facility in Kenya, aiming to produce up to 500 million doses of vaccines annually for the African continent. This initiative, made in partnership with the U.S. Government, focuses on enhancing local manufacturing capabilities to ensure equitable access to vaccines. The facility will initially handle drug substance manufacturing and may expand to include fill/finish services. Moderna's commitment is a significant step towards improving global health equity and preparing for future health crises.
Moderna (NASDAQ:MRNA) announced plans to create an Enterprise Solutions Hub in Atlanta, Georgia, supporting the U.S., Canada, and Latin America. The hub aims to hire 150-200 employees over two years, focusing on finance, human resources, procurement, and digital functions. CEO Stéphane Bancel highlighted the need for business services aligned with skilled talent. The Atlanta hub complements an existing hub in Warsaw, Poland. Moderna anticipates expanding its commercial subsidiaries globally, emphasizing the strategic choice of Atlanta for its diverse and skilled workforce.
FAQ
What is the current stock price of Moderna (MRNA)?
What is the market cap of Moderna (MRNA)?
